Market to stay in sideways zone without earnings boost; CDMO’s the best way to play pharma: Dipan Mehta
Dipan Mehta of Elixir Equities suggests the pharma sector is facing headwinds from potential US tariffs, impacting margins amid strong
Dipan Mehta of Elixir Equities suggests the pharma sector is facing headwinds from potential US tariffs, impacting margins amid strong
Market expert Hemang Jani suggests Laurus Labs' earnings may improve with new launches. API business is also showing promise. He
Saurabh Mukherjea suggests that China's manufacturing advantage, stemming from artificially lowered costs, poses a challenge to democracies. He anticipates China
Rajat Sharma, Founder & CEO of Sana Securities, favors investments in private banking and consumption sectors. He avoids auto, steel,
So, our sense of the markets is let us say from the peak of the market, Sensex would have fallen
Milind Karmarkar of Dalal & Broacha predicts market corrections are temporary, pointing to previous trends where corrections preceded growth. Despite
Markets remain volatile amid FII outflows and global uncertainty, while DII inflows continue to support Indian equities. Earnings recovery, tax
I just want to wait and watch how this thing particular plays out before maybe committing a higher exposure to
I do not think anyone in the market, was expecting the slabs to go to Rs 12 lakh, so it
Gurmeet Chadha advises investors to consider banks over NBFCs in the current market due to better stability and reasonable valuations.
No posts found.